IMMUNO-ONCOLOGY INSIGHTS

Next gen I-O approaches: what will follow the PD-1s?

Guest Editor:
Alfredo Perales-Puchalt, MD, PhD, Vice President Research & Development, Geneos Therapeutics
Alfredo Perales-Puchalt
MD, PhD, Vice President Research & Development, Geneos Therapeutics
November 2020

  • Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

    I Roodink,
    Ilse Roodink
    Scientific Director, ImmunoPrecise Antibodies
    Ilse Roodink obtained a PhD in Medical Sciences at the Radboud University of Nijmegen, The Netherlands in 2009 and continued her research as a postdoctoral researcher developing an in vitro platform to isolate single domain antibodies specifically recognizing tumor targets in its native conformation using phage display technology. In 2013, Ilse joined ImmunoPrecise Antibodies (Europe) as a scientist actively involved in phage display-oriented antibody discovery projects. She was promoted to Scientific Director in 2019, where she is responsible for contract research project execution and management. Ilse is also actively involved in integration of innovative technologies supporting antibody characterization and engineering.
    P Ott,
    Patrick Ott
    Clinical Director, Dana-Farber Cancer Institute
    Dr. Patrick Ott is currently the Clinical Director of both the Melanoma Disease Center and the Center for Immuno-Oncology at DFCI, serves as attending physician in the Department of Medicine at Brigham and Women’s Hospital, and has an appointment as Associate Professor at Harvard Medical School in Boston, MA. Dr. Ott received his MD and PhD from Ludwig Maximilians University of Munich, Germany. He completed post-doctoral training in Immunology and residency training in Medicine at Case Western Reserve University. After a fellowship in Hematology-Oncology and 4 years on the faculty at New York University, he moved to Dana Farber Cancer Institute (DFCI) in 2012.He is a clinical investigator and an integral member of the clinical trials program at Dana Farber/Harvard Cancer Center, where he designs and conducts phase 1 immunotherapy trials for patients with melanoma and a wide range of other tumors. His primary research interests are in melanoma and immunotherapy, specifically the development of innovative tumor vaccine approaches. Dr. Ott has been the Principal Investigator of a first in man clinical trial testing a personalized neoantigen vaccine (NeoVax) in patients with melanoma. The results of the study, reported in in Nature in 2017, established the feasibility and safety of this novel cancer vaccine approach for the first time in a coordinated clinical trial setting. Strong and consistent immunogenicity was demonstrated in patients with high risk melanoma, providing the basis for further testing of this innovative new treatment concept in other cancers. He has been the Principal Investigator and co-investigator on over 30 treatment trials, including those that have been instrumental in the clinical development of the newly FDA approved drugs pembrolizumab and nivolumab for the treatment of advanced melanoma, small cell lung cancer, and many other cancers. This work has resulted in numerous high impact publications including the New England Journal of Medicine, the Lancet Oncology, and the Journal of Clinical Oncology.
    N Senutovitch
    Nina Senutovitch
    Senior Scientist, Sartorius
    Dr. Nina Senutovitch received her BS in Biochemistry from New Mexico State University. She completed her PhD in Biological Sciences from Carnegie Mellon University, where she developed and detailed the function of novel fluorescent probes. As a post-doctoral fellow at the University of Pittsburgh, she established biosensor-based live cell screening assays for the detection of hepatotoxicity, including the use of a human liver “organ on a chip” model. She joined Sartorius in 2019 as a Senior Scientist in Cell Analytics
    1 December 2020
    Innovator Insight
  • DNA-encoded immunotherapeutics: ready for blast-off?

    D Guimet,
    Diana Guimet
    Inovio Pharmaceuticals
    T Smith,
    Trevor RF Smith
    Inovio Pharmaceuticals
    J Skolnik
    Jeffrey M. Skolnik
    Inovio Pharmaceuticals
    1 December 2020
    Expert Insight
  • Reducing the complexity of bispecific antibody manufacture for cancer therapy

    S Ante Lundberg
    Sven Ante Lundberg
    President, Chief Executive Officer, Principal Financial Officer & Executive Director, Merus
    27 November 2020
    Interview
  • Neoantigen vaccines for cancer: ready for primetime

    A Perales- Puchalt,
    Alfredo Perales-Puchalt
    Author for correspondence Geneos Therapeutics. Plymouth Meeting, PA, USA peralespuchalt@geneostx.com
    N Cooch,
    Neil Cooch
    Geneos Therapeutics. Plymouth Meeting, PA, USA
    A Shende et al.
    Ashwini Shende
    Geneos Therapeutics. Plymouth Meeting, PA, USA
    19 November 2020
    Expert Insight
  • Gamma–delta T cells in immuno-oncology: opportunity for next generation immune modulators

    A Truneh,
    Alemseged Truneh
    ImCheck Therapeutics
    A De Gassart,
    Aude De Gassart
    ImCheck Therapeutics
    P Frohna et al.
    Paul Frohna
    ImCheck Therapeutics
    19 November 2020
    Expert Insight
  • Keys to successful clinical translation of next-gen oncolytic virotherapies

    J Stritzker
    Jochen Stritzker
    Senior Vice President Immunotherapy, Themis
    10 September 2020
    Interview